{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:12:55Z","timestamp":1794276775656,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-120"],"award-info":[{"award-number":["2022-PUMCH-B-120"]}]},{"DOI":"10.13039\/501100018567","name":"Special Fund for Scientific Innovation Strategy-Construction of High-level Academy of Agriculture Science","doi-asserted-by":"publisher","award":["CIFMS: 2021-I2M-C&T-A-002"],"award-info":[{"award-number":["CIFMS: 2021-I2M-C&T-A-002"]}],"id":[{"id":"10.13039\/501100018567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13365-023-01180-w","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T17:01:37Z","timestamp":1698512497000},"page":"692-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy in China"],"prefix":"10.1007","volume":"29","author":[{"given":"Siyuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mange","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.coviro.2020.02.005","volume":"40","author":"ES Beck","year":"2020","unstructured":"Beck ES, Cortese I (2020) Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol 40:19\u201327","journal-title":"Curr Opin Virol"},{"key":"1180_CR2","first-page":"1","volume":"81","author":"KM Bennett","year":"2020","unstructured":"Bennett KM, Fernandes PM (2020) Novel treatments for progressive multifocal leukoencephalopathy. Br J Hosp Med 81:1\u20139","journal-title":"Br J Hosp Med"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ana.26198","volume":"90","author":"R Bernard-Valnet","year":"2021","unstructured":"Bernard-Valnet R, Koralnik IJ, Du Pasquier R (2021) Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol 90:865\u2013873","journal-title":"Ann Neurol"},{"key":"1180_CR4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001021","volume":"8","author":"M Beudel","year":"2021","unstructured":"Beudel M, R\u00f6vekamp F, van de Beek D, Brouwer M (2021) Single-dose pembrolizumab treatment for progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 8:e1021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1180_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.26512","volume":"93","author":"X Boumaza","year":"2023","unstructured":"Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, S\u00fchs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G (2023) Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann Neurol 93:257\u2013270","journal-title":"Ann Neurol"},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fimmu.2020.01223","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen H, Moussa M, Catalfamo M (2020) The role of immunomodulatory receptors in the pathogenesis of HIV infection: a therapeutic opportunity for HIV cure? Front Immunol 11:1223\u20131223","journal-title":"Front Immunol"},{"key":"1180_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597\u20131605","journal-title":"N Engl J Med"},{"key":"1180_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A (2021) Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 17:37\u201351","journal-title":"Nat Rev Neurol"},{"key":"1180_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13365-021-01028-1","volume":"28","author":"S Darcy","year":"2022","unstructured":"Darcy S, Alexander M, McCarthy A, O\u2019Dowd S (2022) Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases. J Neurovirol 28:145\u2013150","journal-title":"J Neurovirol"},{"key":"1180_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3389\/fneur.2018.00471","volume":"9","author":"S Fan","year":"2018","unstructured":"Fan S, Qiao X, Liu L, Wu H, Zhou J, Sun R, Chen Q, Huang Y, Mao C, Yuan J, Lu Q, Ge Y, Li Y, Ren H, Wang J, Cui L, Zhao W, Guan H (2018) Next-generation sequencing of cerebrospinal fluid for the diagnosis of neurocysticercosis. Front Neurol 9:471","journal-title":"Front Neurol"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ajco.13375","volume":"16","author":"S Fan","year":"2020","unstructured":"Fan S, Ren H, Zhao L, Yin J, Feng G, Wang J, Guan H (2020a) Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature. Asia Pac J Clin Oncol 16:291\u2013298","journal-title":"Asia Pac J Clin Oncol"},{"key":"1180_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s13365-020-00855-y","volume":"26","author":"S Fan","year":"2020","unstructured":"Fan S, Yuan H, Liu L, Li H, Wang S, Zhao W, Wu Y, Wang P, Hu Y, Han J, Lyu Y, Zhang W, Chen P, Wu H, Gong Y, Ma Z, Li Y, Yu J, Qiao X, Li G, Zhao Y, Wang D, Ren H, Peng B, Cui L, Wang J, Guan H (2020b) Pseudorabies virus encephalitis in humans: a case series study. J Neurovirol 26:556\u2013564","journal-title":"J Neurovirol"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/JVI.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256\u20137263","journal-title":"J Virol"},{"key":"1180_CR14","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/ene.14433","volume":"27","author":"N Grassl","year":"2020","unstructured":"Grassl N, Bunse L, Beutel T, Klockziem M, Gass A, Platten M, Eisele P (2020) Nivolumab for treatment of progressive multifocal leukoencephalopathy in S\u00e9zary syndrome. Eur J Neurol 27:2373\u20132374","journal-title":"Eur J Neurol"},{"key":"1180_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","volume":"25","author":"E Hoang","year":"2019","unstructured":"Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB (2019) Progressive multifocal leukoencephalopathy treated with nivolumab. J Neurovirol 25:284\u2013287","journal-title":"J Neurovirol"},{"key":"1180_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fimmu.2020.00487","volume":"11","author":"JM Jubel","year":"2020","unstructured":"Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA (2020) The role of PD-1 in acute and chronic infection. Front Immunol 11:487","journal-title":"Front Immunol"},{"key":"1180_CR17","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/598335","volume":"48","author":"N Khanna","year":"2009","unstructured":"Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH (2009) Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 48:1459\u20131466","journal-title":"Clin Infect Dis"},{"key":"1180_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000628","volume":"6","author":"C K\u00fcpper","year":"2019","unstructured":"K\u00fcpper C, Heinrich J, Kamm K, B\u00fccklein V, Rothenfusser S, Straube A (2019) Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 6:e628","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1180_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3201\/eid2801.204809","volume":"28","author":"N Lambert","year":"2022","unstructured":"Lambert N, Dauby S, Dive D, Sadzot B, Maquet P (2022) Atezolizumab treatment for progressive multifocal leukoencephalopathy. Emerg Infect Dis 28:253\u2013256","journal-title":"Emerg Infect Dis"},{"key":"1180_CR20","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1111\/ene.15021","volume":"28","author":"N Lambert","year":"2021","unstructured":"Lambert N, El Moussaoui M, Maquet P (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: identifying relevant outcome factors. Eur J Neurol 28:3814\u20133819","journal-title":"Eur J Neurol"},{"key":"1180_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000756","volume":"7","author":"C Mahler","year":"2020","unstructured":"Mahler C, Andrews M, Henson SM, Gnanapavan S (2020) Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 7:e756","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1180_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","volume":"17","author":"EO Major","year":"2018","unstructured":"Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467\u2013480","journal-title":"Lancet Neurol"},{"key":"1180_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3201\/eid2408.180460","volume":"24","author":"M Martinot","year":"2018","unstructured":"Martinot M, Ahle G, Petrosyan I, Martinez C, Gorun DM, Mohseni-Zadeh M, Fafi-Kremer S, Tebacher-Alt M (2018) Progressive multifocal leukoencephalopathy after treatment with nivolumab. Emerg Infect Dis 24:1594\u20131596","journal-title":"Emerg Infect Dis"},{"key":"1180_CR24","doi-asserted-by":"publisher","first-page":"175628642199368","DOI":"10.1177\/1756286421993684","volume":"14","author":"N M\u00f6hn","year":"2021","unstructured":"M\u00f6hn N, Wattjes MP, Adams O, Nay S, Tkachenko D, Salge F, Heine J, Pars K, H\u00f6glinger G, Respondek G, Stangel M, Skripuletz T, Jacobs R, S\u00fchs KW (2021) PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord 14:1756286421993684","journal-title":"Ther Adv Neurol Disord"},{"key":"1180_CR25","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/v14050970","volume":"14","author":"C Pinnetti","year":"2022","unstructured":"Pinnetti C, Cimini E, Vergori A, Mazzotta V, Grassi G, Mondi A, Forbici F, Amendola A, Grisetti S, Baldini F, Candela C, Casetti R, Campioni P, Capobianchi MR, Agrati C, Antinori A (2022) Use of pembrolizumab for treatment of progressive multifocal leukoencephalopathy in people living with HIV. Viruses 14:970","journal-title":"Viruses"},{"key":"1180_CR26","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00415-021-10414-y","volume":"268","author":"D Roos-Weil","year":"2021","unstructured":"Roos-Weil D, Weiss N, Guihot A, Uzunov M, Bellanger A, Eymard B, Saadoun D, Houillier C, Idbaih A, Demeret S, Deback C, Leblond V, Galanaud D, Shor N, Pourcher V (2021) Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard? J Neurol 268:2458\u20132465","journal-title":"J Neurol"},{"key":"1180_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00415-018-9140-0","volume":"266","author":"N Sanjo","year":"2019","unstructured":"Sanjo N, Nose Y, Shishido-Hara Y, Mizutani S, Sekijima Y, Aizawa H, Tanizawa T, Yokota T (2019) A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy. J Neurol 266:369\u2013377","journal-title":"J Neurol"},{"key":"1180_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/jha2.485","volume":"3","author":"E Vinatier","year":"2022","unstructured":"Vinatier E, Poli C, Giltat A, Nunes-Gomes C, Orvain C, Hunault-Berger M, Jeannin P, Th\u00e9pot S (2022) Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: a consequence of an immune reconstitution inflammatory syndrome? Ejhaem 3:958\u2013961","journal-title":"Ejhaem"},{"key":"1180_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00415-021-10682-8","volume":"269","author":"T Volk","year":"2021","unstructured":"Volk T, Warnatz K, Marks R, Urbach H, Schluh G, Strohmeier V, Rojas-Restrepo J, Grimbacher B, Rauer S (2021) Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and\/or hematologic malignancy: a case series of five patients. J Neurol 269:973\u2013981","journal-title":"J Neurol"},{"key":"1180_CR30","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMc1816198","volume":"380","author":"O Walter","year":"2019","unstructured":"Walter O, Treiner E, Bonneville F, Mengelle C, Vergez F, Lerebours F, Delobel P, Liblau R, Martin-Blondel G (2019) Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med 380:1674\u20131676","journal-title":"N Engl J Med"},{"key":"1180_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086","journal-title":"Cancer Discov"},{"key":"1180_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486\u2013499","journal-title":"Nat Rev Immunol"},{"key":"1180_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18:91\u2013104","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-023-01180-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-023-01180-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-023-01180-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T14:26:33Z","timestamp":1705501593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-023-01180-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s13365-023-01180-w","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}